Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
| ▸ | CCR6 | P51684 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084265 | 0.93 | KIF11 (0.53) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9060861 | 0.87 | NFE2L2 (0.62) | MAPTNPC1RAB9ALMNA | |
| SCHEMBL9073469 | 0.87 | MAPT (0.68) | CHRNA7L3MBTL1MAPTEPHX2NPC1 | |
| SCHEMBL9060858 | 0.87 | NFE2L2 (0.62) | MAPTNPC1RAB9ALMNA | |
| SCHEMBL9062440 | 0.87 | GRIN2B (0.56) | GRIN2BLMNA | |
| SCHEMBL2056112 | 0.87 | CHRNA7 (0.49) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10300052 | 0.87 | APP (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL254957 | 0.86 | MAPT (0.56) | L3MBTL1MAPTEPHX2TDP1GAA | |
| SCHEMBL12204656 | 0.85 | PDE2A (0.51) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2016489 | 0.84 | VNN1 (0.63) | CA1CA2GRIN2BMAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260088362-A1 | ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY | MURATA MANUFACTURING CO (JP) | 2026-03-26 | — | — | US | claimed |
| WO-2025013623-A1 | ELECTROLYTE SOLUTION FOR SECONDARY BATTERIES, AND SECONDARY BATTERY | 株式会社村田製作所 | 2025-01-16 | — | — | WO | claimed |
| CN-114733578-B | Vulcanizing liquid and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-114733578-A | Vulcanizing liquid and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-07-12 | — | — | CN | claimed |
| US-9169209-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2015-10-27 | — | — | US | claimed |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2014-09-18 | — | — | US | claimed |
| US-8450303-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-28 | — | — | US | claimed |
| US-8426401-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV | 2013-04-23 | — | — | US | claimed |
| WO-2012150952-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2012-11-08 | — | — | WO | claimed |
| WO-2012054782-A2 | FLUOROALKOXYLATION OF ORGANIC COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-04-26 | — | — | WO | claimed |
| EP-2421860-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| EP-2421856-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100331299-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | claimed |
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| EP-2252595-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | claimed |
| WO-2010124082-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| WO-2010124112-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | claimed |
| WO-2009097578-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-06 | — | — | WO | claimed |
| US-20260088362-A1 | ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY | MURATA MANUFACTURING CO (JP) | 2026-03-26 | — | — | US | disclosed |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4299135-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-116903499-B | Anhydrous fluorosulfonyl difluoro copper acetate salt, preparation method and application thereof | 上海应用技术大学 | 2025-05-30 | — | — | CN | disclosed |
| EP-3986890-B9 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-3461809-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025013623-A1 | ELECTROLYTE SOLUTION FOR SECONDARY BATTERIES, AND SECONDARY BATTERY | 株式会社村田製作所 | 2025-01-16 | — | — | WO | disclosed |
| US-20240392220-A1 | BRANDY REPLICAS | AVA FOOD LABS, INC. | 2024-11-28 | — | — | US | disclosed |
| CN-114364672-B | Benzisoxazole sulfonamide derivatives | 辉瑞大药厂 | 2024-09-06 | — | — | CN | disclosed |
| EP-4408967-A1 | BRANDY REPLICAS | AVA FOOD LABS, INC. (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-118339274-A | Brandy replica | 艾娃食品实验室股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-114733578-B | Vulcanizing liquid and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4299135-A2 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-114702364-B | Preparation method of polyfluoroalkyl aromatic hydrocarbon | 闽都创新实验室 | 2024-01-02 | — | — | CN | disclosed |
| WO-2023237580-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2023-12-14 | — | — | WO | disclosed |
| EP-3986890-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3986890-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-117024312-A | Aryl sulfonyl fluoride and preparation method using aryl sulfonium salt as substrate | 上海应用技术大学 | 2023-11-10 | — | — | CN | disclosed |
| CN-117024237-A | Aryl sulfonyl fluoride and preparation method using aryl iodonium salt as raw material | 上海应用技术大学 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-116903499-A | Anhydrous fluorosulfonyl difluoro copper acetate salt, preparation method and application thereof | 上海应用技术大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-116253606-A | Preparation method of aryl difluoromethyl alkyl sulfonyl fluoride compound | 上海应用技术大学 | 2023-06-13 | — | — | CN | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| CN-115043834-B | Naphthyridinamide compound and preparation method and application thereof | 中国农业大学 | 2023-06-06 | — | — | CN | disclosed |
| WO-2023055801-A1 | BRANDY REPLICAS | AVA FOOD LABS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| CN-113603619-B | Method for preparing aryl sulfonyl fluoride by taking aryl hydrazine hydrochloride as raw material | 上海应用技术大学 | 2023-02-10 | — | — | CN | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-113698325-B | Method for preparing alkyl sulfonyl fluoride | 上海应用技术大学 | 2022-12-16 | — | — | CN | disclosed |
| US-11492346-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2022-11-08 | — | — | US | disclosed |
| CN-115043834-A | Naphthyridine amide compound and preparation method and application thereof | 中国农业大学 | 2022-09-13 | — | — | CN | disclosed |
| CN-114733578-A | Vulcanizing liquid and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3986890-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114364672-A | Benzisoxazole sulfonamide derivatives | 辉瑞大药厂 | 2022-04-15 | — | — | CN | disclosed |
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-22 | — | — | US | disclosed |
| CN-108329312-B | Tetracycline compounds | 四相制药公司 | 2021-12-31 | — | — | CN | disclosed |
| US-11185514-B2 | Aqueous solution comprising a polyphenol | OPTERION HEALTH AG (CH) | 2021-11-30 | — | — | US | disclosed |
| CN-113698325-A | Method for preparing alkyl sulfonyl fluoride | 上海应用技术大学 | 2021-11-26 | — | — | CN | disclosed |
| CN-113603619-A | Method for preparing aryl sulfonyl fluoride by taking aryl hydrazine hydrochloride as raw material | 上海应用技术大学 | 2021-11-05 | — | — | CN | disclosed |
| US-11160766-B2 | Peritoneal therapeutic fluid | OPTERION HEALTH AG (CH) | 2021-11-02 | — | — | US | disclosed |
| CN-109134316-B | Fluoroalkyl sulfonyl fluoride compound and intermediate, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2021-11-02 | — | — | CN | disclosed |
| EP-3442955-B1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | US HEALTH (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-10913712-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913712-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3048107-B1 | BENZOBIS (THIADIAZOLE) DERIVATIVE, INK CONTAINING SAME, AND ORGANIC ELECTRONIC DEVICE USING SAME | FUTURE INK CORP (JP) | 2021-01-13 | — | — | EP | disclosed |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2020-12-24 | — | — | US | disclosed |
| WO-2020254946-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254946-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3421458-B1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-11 | — | — | EP | disclosed |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10811669-B2 | Battery and method for manufacturing same | NEC CORPORATION (JP) | 2020-10-20 | — | — | US | disclosed |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-08 | — | — | US | disclosed |
| US-10777850-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-09-15 | — | — | US | disclosed |
| US-10741879-B2 | Secondary battery and production method therefor | NEC CORPORATION (JP) | 2020-08-11 | — | — | US | disclosed |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-04 | — | — | US | disclosed |
| US-10731159-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-3247702-B1 | PESTICIDALLY ACTIVE SEMI-CARBAZONES AND THIOSEMICARBAZONES DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-04-22 | — | — | EP | disclosed |
| US-20200108026-A1 | AQUEOUS SOLUTION COMPRISING A POLYPHENOL | OPTERION HEALTH AG (CH) | 2020-04-09 | — | — | US | disclosed |
| CN-107573267-B | Trifluoromethyl-containing alkyl sulfonyl fluoride compound, and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2020-03-10 | — | — | CN | disclosed |
| US-20200048193-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20200048193-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| WO-2019182035-A1 | METHOD FOR PRODUCING AROMATIC HYDROXY COMPOUND | 宇部興産株式会社 | 2019-09-26 | — | — | WO | disclosed |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| EP-2968316-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10370333-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (US) | 2019-08-06 | — | — | US | disclosed |
| US-10315992-B2 | Tetracyline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10315992-B2 | Tetracyline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190152937-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-23 | — | — | US | disclosed |
| EP-3461809-A1 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-3461809-A1 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20190051941-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-02-14 | — | — | US | disclosed |
| US-10177414-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3421458-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | Janssen Pharmaceutica NV (BE) | 2019-01-02 | — | — | EP | disclosed |
| US-10155737-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-18 | — | — | US | disclosed |
| EP-3051618-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | MITSUBISHI CHEM CORP (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-2890673-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20180221303-A1 | PERITONEAL THERAPEUTIC FLUID | OPTERION HEALTH AG (CH) | 2018-08-09 | — | — | US | disclosed |
| US-20180221303-A1 | PERITONEAL THERAPEUTIC FLUID | OPTERION HEALTH AG (CH) | 2018-08-09 | — | — | US | disclosed |
| US-20180214387-A1 | AQUEOUS SOLUTION COMPRISING A POLYPHENOL | OPTERION HEALTH AG (CH) | 2018-08-02 | — | — | US | disclosed |
| US-20180214387-A1 | AQUEOUS SOLUTION COMPRISING A POLYPHENOL | OPTERION HEALTH AG (CH) | 2018-08-02 | — | — | US | disclosed |
| US-20180219160-A1 | BENZOBIS(THIADIAZOLE) DERIVATIVE, INK COMPRISING THE SAME, AND ORGANIC ELECTRONIC DEVICE USING THE SAME | UBE INDUSTRIES, LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-9978954-B2 | Benzobis (thiadiazole) derivative, ink comprising same, and organic electronic device comprising same | UBE INDUSTRIES, LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| EP-2970157-B1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-25 | — | — | EP | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-20180051285-A1 | CATIONIC LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-22 | — | — | US | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| EP-2935257-B1 | CYCLIC SULFONAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2018-02-07 | — | — | EP | disclosed |
| US-9884826-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884826-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-02-06 | — | — | US | disclosed |
| US-20180026256-A1 | BATTERY AND METHOD FOR MANUFACTURING SAME | NEC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| CN-107540639-A | The manufacture method of oxabicyclo octane compound | 宇部兴产株式会社 | 2018-01-05 | — | — | CN | disclosed |
| EP-3098893-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING SAME | MITSUBISHI CHEM CORP (JP) | 2017-11-29 | — | — | EP | disclosed |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170317387-A1 | SECONDARY BATTERY AND PRODUCTION METHOD THEREFOR | NEC CORPORATION (JP) | 2017-11-02 | — | — | US | disclosed |
| WO-2017189613-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | GUANGDONG GOOD MEDICINE AND HEALTH TECHNOLOGY CO., LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20170305852-A1 | Tetracyline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170305852-A1 | Tetracyline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170305852-A1 | Tetracyline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9758453-B2 | One-component reagent for the fluoroalkylation reaction | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-09-12 | — | — | US | disclosed |
| US-9714252-B2 | Cyclic sulfonamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9695129-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695129-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL INC. (US) | 2017-07-04 | — | — | US | disclosed |
| EP-3181569-A1 | BENZOBIS(THIADIAZOLE) DERIVATIVE, INK CONTAINING SAME, AND ORGANIC ELECTRONIC DEVICE USING SAME | UBE Industries, Ltd. (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-20170088531-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-30 | — | — | US | disclosed |
| US-9573895-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573895-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573895-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9562053-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-07 | — | — | US | disclosed |
| US-20160355479-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-12-08 | — | — | US | disclosed |
| US-20160355479-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-12-08 | — | — | US | disclosed |
| EP-3098893-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SOLUTION SECONDARY BATTERY USING SAME | Mitsubishi Chemical Corporation (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9493419-B2 | Quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-11-15 | — | — | US | disclosed |
| US-20160322669-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-11-03 | — | — | US | disclosed |
| US-9458147-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| US-9461334-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9458147-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160276598-A1 | BENZOBIS (THIADIAZOLE) DERIVATIVE, INK COMPRISING SAME, AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | FUTURE INK CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
| US-20160251317-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL INC (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251317-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL INC (US) | 2016-09-01 | — | — | US | disclosed |
| EP-3051618-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | Mitsubishi Chemical Corporation (JP) | 2016-08-03 | — | — | EP | disclosed |
| EP-3048107-A1 | BENZOBIS (THIADIAZOLE) DERIVATIVE, INK CONTAINING SAME, AND ORGANIC ELECTRONIC DEVICE USING SAME | UBE Industries, Ltd. (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20160211553-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185691-A1 | One-Component Reagent for the Fluoroalkylation Reaction | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF LLLINOIS (US) | 2016-06-30 | — | — | US | disclosed |
| US-9359305-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359305-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160140326-A1 | SIMULATED CARBON AND PROTON NMR CHEMICAL SHIFTS BASED BINARY FINGERPRINTS FOR VIRTUAL SCREENING | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-05-19 | — | — | US | disclosed |
| EP-3020701-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-20160107988-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160107988-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160107988-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| US-9249103-B2 | Compounds, compositions and associated methods comprising 3-aryl quinolines | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2970157-A2 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150336974-A1 | Cyclic Sulfonamides as Sodium Channel Blockers | PURDUE PHARMA L.P. | 2015-11-26 | — | — | US | disclosed |
| US-9193648-B2 | Fluoroalkylation methods and reagents | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2015-11-24 | — | — | US | disclosed |
| US-9169209-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150166485-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL LIMITED (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166485-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL LIMITED (US) | 2015-06-18 | — | — | US | disclosed |
| US-9000187-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000187-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| WO-2015048547-A2 | METHODS FOR USING AND BIOMARKERS FOR AMPK-ACTIVATING COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| WO-2015031725-A1 | TRANSITION METAL-CATALYZED IMIDATION OF ARENES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-05 | — | — | WO | disclosed |
| WO-2015031725-A1 | TRANSITION METAL-CATALYZED IMIDATION OF ARENES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-05 | — | — | WO | disclosed |
| CN-104364239-A | New diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN LA ROCHE | 2015-02-18 | — | — | CN | disclosed |
| EP-2500345-B1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2015-01-28 | — | — | EP | disclosed |
| WO-2015005253-A1 | NOVEL LIPID | 第一三共株式会社 (JP) | 2015-01-15 | — | — | WO | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford- Burnham Medical Reseach Institute (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford- Burnham Medical Reseach Institute (US) | 2015-01-08 | — | — | US | disclosed |
| US-20140350048-A1 | COMPOUNDS, COMPOSITIONS AND ASSOCIATED METHODS COMPRISING 3-ARYL QUINOLINES | OREGON HEALTH & SCIENCE UNIVERSITY | 2014-11-27 | — | — | US | disclosed |
| WO-2014184070-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184071-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| US-20140343278-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARMA CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARCACEUTICAL CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20140343278-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARMA CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARCACEUTICAL CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| WO-2014164749-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014164767-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014159061-A2 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140275172-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-8822453-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822453-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8785634-B2 | Spiropiperidine prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2014096941-A1 | CYCLIC SULFONAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-2746272-A1 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-8697683-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-15 | — | — | US | disclosed |
| US-8697684-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-15 | — | — | US | disclosed |
| WO-2014036502-A2 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| EP-2697207-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | Chong Kun Dang Pharmaceutical Corp. (KR) | 2014-02-19 | — | — | EP | disclosed |
| CN-103596960-A | 6, 7-dihydroimidazo [2,1-B ] [1,3] oxazine fungicides | OTSUKA PHARMA CO LTD | 2014-02-19 | — | — | CN | disclosed |
| US-8618290-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-31 | — | — | US | disclosed |
| US-20130281392-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL LIMITED (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281392-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL LIMITED (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130237517-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130225815-A1 | Fluoroalkylation Methods And Reagents | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013126608-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-08-29 | — | — | WO | disclosed |
| US-20130217669-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2606048-A1 | FLUOROALKYLATION METHODS AND REAGENTS | The Board of Trustees of the University of Illinois (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8450303-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8426401-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV | 2013-04-23 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-20130023515-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-01-24 | — | — | US | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-102869667-A | Tricyclic pyridine derivatives, medicaments containing these compounds, their use and processes for their preparation | BOEHRINGER INGELHEIM INT | 2013-01-09 | — | — | CN | disclosed |
| WO-2012150952-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120264770-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| WO-2012141487-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2012-10-18 | — | — | WO | disclosed |
| EP-2500345-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2495323-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-8247431-B2 | Heterocyclic hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8242103-B2 | Sulphamides for treatment of cancer | MERCK SHARP & DOHME LIMITED (GB) | 2012-08-14 | — | — | US | disclosed |
| US-20120172321-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120165370-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-06-28 | — | — | US | disclosed |
| WO-2012083866-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-06-28 | — | — | WO | disclosed |
| US-8188273-B2 | Insecticidal (1,3,5)-triazinyl phenyl hydrazones | DOW AGROSCIENCES, LLC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2012054782-A2 | FLUOROALKOXYLATION OF ORGANIC COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054782-A2 | FLUOROALKOXYLATION OF ORGANIC COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-04-26 | — | — | WO | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2421860-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | disclosed |
| EP-2421856-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012024564-A1 | FLUOROALKYLATION METHODS AND REAGENTS | THE BOARD OF TRUSTESS OF THE UNIVERSITY OF ILLINOIS (US) | 2012-02-23 | — | — | WO | disclosed |
| EP-2420493-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| WO-2012021712-A1 | TETRACYCLINE ANALOGS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040837-A1 | INSECTICIDAL (1,3,5)-TRIAZINYL PHENYL HYDRAZONES | DOW AGROSCIENCES LLC (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2144898-B1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-8071766-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-06 | — | — | US | disclosed |
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| EP-2336104-A1 | ORTHO-SUBSTITUTED HALOALKYLSULFONANILIDE DERIVATIVE AND HERBICIDE | Nissan Chemical Industries, Ltd. (JP) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011059021-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2011-05-19 | — | — | WO | disclosed |
| US-20110053873-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| WO-2011021726-A2 | NITROGEN-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-24 | — | — | WO | disclosed |
| US-7888374-B2 | Inhibitors of c-jun N-terminal kinases | ABBOTT LABORATORIES (US) | 2011-02-15 | — | — | US | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100331299-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | disclosed |
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| EP-2252595-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010124082-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124112-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| WO-2009097578-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-06 | — | — | WO | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080132538-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC | 2008-06-05 | — | — | US | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| WO-2007043542-A9 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2008-05-08 | — | — | WO | disclosed |
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| US-7342031-B2 | Thiadiazole compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-11 | — | — | US | disclosed |
| EP-1885349-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | Merck Sharp & Dohme Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| US-20070293510-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) | 2007-12-20 | — | — | US | disclosed |
| WO-2007119001-A2 | AMINOMETHYL PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-10-25 | — | — | WO | disclosed |
| US-7279475-B2 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279475-B2 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279475-B2 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7273879-B2 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-25 | — | — | US | disclosed |
| EP-1831157-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | Pfizer Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1268412-B8 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-7176224-B2 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists | ELI LILLY AND COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| WO-2006123185-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| EP-1268412-B1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-7138400-B2 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| US-20060257987-A1 | Ppar modulators | ELI LILLY AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006067587-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | PFIZER LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| EP-1638944-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20060014962-A1 | Thiadiazole compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-01-19 | — | — | US | disclosed |
| US-20050256162-A1 | Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| US-20050215578-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1334085-B1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2005-08-24 | — | — | EP | disclosed |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | XIN ZHILI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1551836-A1 | AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| EP-1549621-A1 | FLUORINATED PHENYL-NAPHTHALENYL-UREA COMPOUNDS AS INHIBITORS OF CYTOKINES INVOLVED IN INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1550661-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
| US-6872726-B2 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-03-29 | — | — | US | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050032797-A1 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005000821-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-0888338-B1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-1475374-A1 | THIADIAZOLE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040077647-A1 | Cytokine inhibitors, antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004031190-A1 | AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-03-11 | — | — | US | disclosed |
| WO-2004014870-A1 | FLUORINATED PHENYL-NAPHTHALENYL-UREA COMPOUNDS AS INHIBITORS OF CYTOKINES INVOLVED IN INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK CANADA INC. (CA) | 2004-02-12 | — | — | US | disclosed |
| US-20030199540-A1 | Fluoroalkyoxybenzylamino derivatives of nitrogen containing heterocycles | LOWE JOHN ADAMS (US) | 2003-10-23 | — | — | US | disclosed |
| EP-1334085-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LTD. (GB) | 2003-08-13 | — | — | EP | disclosed |
| US-20030114439-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC. | 2003-06-19 | — | — | US | disclosed |
| US-6555552-B2 | Psychological disorders; analgesics; antiinflammatory agents | MERCK SHARP & DOHME LTD. (GB) | 2003-04-29 | — | — | US | disclosed |
| EP-0920425-B1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2003-02-19 | — | — | EP | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| EP-1268412-A1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 2003-01-02 | — | — | EP | disclosed |
| EP-0882038-B1 | SUBSTITUTED N-METHYL-N-(4-(PIPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020147212-A1 | Azabicyclic amine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2002-10-10 | — | — | US | disclosed |
| EP-0888336-B1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL-AMINO)P IPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-0874843-B1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6423704-B2 | CROHN'S DISEAS, ANTIULCER AGENTS, ASTHMA, EMESIS | AVENTIS PHARMACEUTICALS INC. | 2002-07-23 | — | — | US | disclosed |
| WO-2002036555-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
| US-20020035147-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC. | 2002-03-21 | — | — | US | disclosed |
| EP-1172106-A2 | Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists | Pfizer Products Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | AVENTIS PHARMACEUTICALS INC. | 2001-10-25 | — | — | US | disclosed |
| US-6297259-B1 | HISTAMINE RECEPTOR ANTAGONISTS AND TACHYKININ RECEPTOR ANTAGONISTS. | AVENTIS PHARMACEUTICALS INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2001070677-A1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 2001-09-27 | — | — | WO | disclosed |
| US-6211199-B1 | HISTAMINE AND TACHYKININ RECEPTOR ANTAGONISTS; ANTIASTHMATICS, ANTIEMETICS; RESPIRATORY SYSTEM DISORDERS, INFLAMMATORY BOWEL DISEASE, CONJUNCTIVITIS | AVENTIS PHARMACEUTICALS INC. | 2001-04-03 | — | — | US | disclosed |
| US-6194406-B1 | HISTAMINE RECEPTOR ANTAGONISTS; TACHYKININ RECEPTOR ANTAGONISTS; ASTHMA; BRONCHITIS; INFLAMMATORY BOWEL DISEASES, INCLUDING CROHN'S DISEASE AND ULCERATIVE COLITIS; SEASONAL RHINITIS; SINUSITIS; ANTIALLERGENS; EMETIC AGENTS | AVENTIS PHARMACEUTICALS INC. | 2001-02-27 | — | — | US | disclosed |
| US-5998439-A | RESPIRATORY SYSTEM DISORDERS | Hoescht Marion Roussel, Inc. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5932571-A | Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases | HOECHST MARION ROUSSEL, INC. (US) | 1999-08-03 | — | — | US | disclosed |
| US-5922737-A | Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases | HOECHST MARION ROUSSEL, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0888338-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0888336-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL-AMINO)P IPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0882038-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(PIPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1998-12-09 | — | — | EP | disclosed |
| EP-0874843-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0690835-B1 | FORMYLATION PROCESS FOR AROMATIC ALDEHYDES | PFIZER (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5773450-A | ANTIINFLAMMATORY AGENTS, CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1998-06-30 | — | — | US | disclosed |
| US-5744480-A | ANTIINFLAMMATORY AGENTS, NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1998-04-28 | — | — | US | disclosed |
| WO-1997030991-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997030989-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997030990-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(PIPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997022604-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-06-26 | — | — | WO | disclosed |
| EP-0589924-B1 | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES | PFIZER (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0690835-A1 | FORMYLATION PROCESS FOR AROMATIC ALDEHYDES | PFIZER INC. (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994024081-A1 | FORMYLATION PROCESS FOR AROMATIC ALDEHYDES | PFIZER INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0589924-A1 | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES. | PFIZER (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5294744-A | Formylation process for aromatic aldehydes | PFIZER INC. (US) | 1994-03-15 | — | — | US | disclosed |
| WO-1993000331-A1 | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES | PFIZER INC. (US) | 1993-01-07 | — | — | WO | disclosed |
| US-4552984-A | SULFONYLATION IN PRESENCE OF BORON TRIFLUORIDE, HYDROGEN FLUORIDE | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-11-12 | — | — | US | disclosed |
| EP-0092627-B1 | PROCESS FOR THE PREPARATION OF DI- OR TRIFLUOROMETHOXYPHENYL KETONES OR OF DI- OR TRIFLUOROMETHYLTHIOPHENYL KETONES | RHONE-POULENC CHIMIE (FR) | 1985-05-29 | — | — | EP | disclosed |
| EP-0084743-B1 | PROCESS FOR THE PREPARATION OF ALPHA, ALPHA-DIFLUOROALKOXY OR ALPHA, ALPHADIFLUOROALKYLTHIOPHENYL SULFONES | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-11-21 | — | — | EP | disclosed |
| US-4446078-A | REACTING A POLYHALOALKOXY- OR POLYHALOALKYLTHIOBENZENE WITH A CARBOXYLIC DERIVATIVE, BORON TRIFLUORIDE | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-05-01 | — | — | US | disclosed |
| US-4438043-A | Process for preparation of di- or trifluoromethoxyphenyl ketones or di- or trifluoromethylthiophenyl ketones | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-20 | — | — | US | disclosed |
| EP-0092627-A1 | Process for the preparation of di- or trifluoromethoxyphenyl ketones or of di- or trifluoromethylthiophenyl ketones | RHONE-POULENC CHIMIE (FR) | 1983-11-02 | — | — | EP | disclosed |
| EP-0085265-A1 | Process for the preparation of alpha,alpha-difluoroalkoxy or alpha,alpha-difluoroalkylthiophenyl ketones | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1983-08-10 | — | — | EP | disclosed |
| EP-0084743-A1 | Process for the preparation of alpha, alpha-difluoroalkoxy or alpha, alphadifluoroalkylthiophenyl sulfones | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1983-08-03 | — | — | EP | disclosed |
| EP-0084743-A1 | Process for the preparation of alpha, alpha-difluoroalkoxy or alpha, alphadifluoroalkylthiophenyl sulfones | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1983-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160276598-A1 | BENZOBIS (THIADIAZOLE) DERIVATIVE, INK COMPRISING SAME, AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | BRD3, TH, BRS3 | CA1 4465/4885CA2 3251/4885CA7 3990/4885 |
| US-11160766-B2 | Peritoneal therapeutic fluid | FABP6, ALB, FABP2 | CA1 491/4885CA2 2279/4885CA7 855/4885 |
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | HRH4, HRH2, HRH1 | CA1 1771/4885CA2 1373/4885CA7 2355/4885 |
| US-10370333-B2 | Sulfonamide compounds and uses as TNAP inhibitors | TNNI3, TNKS1BP1, TNNT2 | CA1 1247/4885CA2 35/4885CA7 1198/4885 |
| US-11185514-B2 | Aqueous solution comprising a polyphenol | SORD, SI, AQP1 | CA1 1659/4885CA2 3012/4885CA7 455/4885 |
| US-20090305998-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | CA1 4587/4885CA2 4094/4885CA7 4552/4885 |
| US-20040077647-A1 | Cytokine inhibitors, antiinflammatory agents | IL1B, IL1A, TNF | CA1 3301/4885CA2 3554/4885CA7 4126/4885 |
| US-20050032797-A1 | Fluorinated di-aryl urea compounds | IL1B, MPO, IL1A | CA1 4401/4885CA2 4503/4885CA7 4089/4885 |
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | BRIX1, RB1, BCR | CA1 2480/4885CA2 1347/4885CA7 629/4885 |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | CA1 4237/4885CA2 4526/4885CA7 4709/4885 |
| US-20030199540-A1 | Fluoroalkyoxybenzylamino derivatives of nitrogen containing heterocycles | FPR1, OPRK1, CNR1 | CA1 2109/4885CA2 2502/4885CA7 3738/4885 |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CA1 4506/4885CA2 3091/4885CA7 1676/4885 |
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | CA1 3455/4885CA2 3923/4885CA7 4278/4885 |
| US-20160257951-A1 | NOVEL LIPID | NPC1L1, CETP, LIPC | CA1 4148/4885CA2 2765/4885CA7 1734/4885 |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | POLM, POLN, PNKP | CA1 4881/4885CA2 4698/4885CA7 4682/4885 |
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CA1 4624/4885CA2 2746/4885CA7 3643/4885 |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | BRIX1, RB1, BCR | CA1 2373/4885CA2 1349/4885CA7 659/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CA1 3493/4885CA2 1853/4885CA7 2152/4885 |
| US-20020147212-A1 | Azabicyclic amine derivatives and their use as therapeutic agents | CXCR1, CXCR6, CCR6 | CA1 285/4885CA2 1024/4885CA7 353/4885 |
| US-20180051285-A1 | CATIONIC LIPID | CETP, NPC1L1, LIPA | CA1 3874/4885CA2 2316/4885CA7 1534/4885 |
| US-10155737-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | CA1 4805/4885CA2 2343/4885CA7 4363/4885 |
| US-20050215578-A1 | Thiadiazole compounds and use thereof | C5, C3AR1, TH | CA1 4786/4885CA2 4499/4885CA7 3031/4885 |
| US-20080132538-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | NMUR2, NMUR1, NMBR | CA1 2346/4885CA2 689/4885CA7 1742/4885 |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | CA1 4805/4885CA2 2343/4885CA7 4363/4885 |
| US-20130217669-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CA1 4624/4885CA2 2746/4885CA7 3643/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CA1 4506/4885CA2 3091/4885CA7 1676/4885 |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | TNNI3, TNKS1BP1, TNNT2 | CA1 1247/4885CA2 35/4885CA7 1198/4885 |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | CA1 3455/4885CA2 3923/4885CA7 4278/4885 |
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | SDHA, SDHB, BRDT | CA1 770/4885CA2 1472/4885CA7 757/4885 |
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | ABCG2, ABCC1, PNPO | CA1 4864/4885CA2 4645/4885CA7 4549/4885 |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | CA1 2541/4885CA2 2943/4885CA7 3383/4885 |
| US-20200108026-A1 | AQUEOUS SOLUTION COMPRISING A POLYPHENOL | SORD, SI, AQP1 | CA1 1659/4885CA2 3012/4885CA7 455/4885 |
| US-20260088362-A1 | ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY | HCN2, HCN1, PEF1 | CA1 2998/4885CA2 3028/4885CA7 3788/4885 |
| US-20190152937-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | CA1 4805/4885CA2 2343/4885CA7 4363/4885 |
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | CA1 1003/4885CA2 706/4885CA7 1307/4885 |
| US-20140350048-A1 | COMPOUNDS, COMPOSITIONS AND ASSOCIATED METHODS COMPRISING 3-ARYL QUINOLINES | CYP3A43, ABL1, CYP3A7 | CA1 4519/4885CA2 2889/4885CA7 1591/4885 |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | CA1 4127/4885CA2 3491/4885CA7 3113/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | CA1 3301/4885CA2 1488/4885CA7 1931/4885 |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | CA1 2375/4885CA2 2965/4885CA7 3277/4885 |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | CA1 669/4885CA2 372/4885CA7 1358/4885 |
| US-20170305852-A1 | Tetracyline Compounds | SLC10A1, CYP3A7, TAAR5 | CA1 1555/4885CA2 911/4885CA7 44/4885 |
| US-20140275172-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | CA1 4805/4885CA2 2343/4885CA7 4363/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CA1 4171/4885CA2 2002/4885CA7 2372/4885 |
| US-10913712-B2 | Tetracycline compounds | TREH, TUBB, TUBB6 | CA1 2662/4885CA2 1136/4885CA7 398/4885 |
| US-20140343278-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | CA1 669/4885CA2 372/4885CA7 1358/4885 |
| US-20150166485-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | LIPC, CYP3A43, CYP51A1 | CA1 2757/4885CA2 1466/4885CA7 1345/4885 |
| US-20020035147-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | AQP4, NAT1, CNR1 | CA1 1600/4885CA2 1208/4885CA7 1689/4885 |
| US-20160107988-A1 | Tetracycline Compounds | TREH, TUBB, TUBB6 | CA1 2662/4885CA2 1136/4885CA7 398/4885 |
| US-20030114439-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | AQP4, NAT1, CNR1 | CA1 1600/4885CA2 1208/4885CA7 1689/4885 |
| US-20170088531-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | CA1 4805/4885CA2 2343/4885CA7 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.